These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15377640)

  • 1. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
    Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
    Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.
    Khan KK; He YQ; Correia MA; Halpert JR
    Drug Metab Dispos; 2002 Sep; 30(9):985-90. PubMed ID: 12167563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract.
    Iwata H; Tezuka Y; Kadota S; Hiratsuka A; Watabe T
    Drug Metab Dispos; 2004 Dec; 32(12):1351-8. PubMed ID: 15342469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
    Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
    Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
    Ma B; Prueksaritanont T; Lin JH
    Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
    Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
    Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
    Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
    AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.
    Hutzler JM; Melton RJ; Rumsey JM; Schnute ME; Locuson CW; Wienkers LC
    Chem Res Toxicol; 2006 Dec; 19(12):1650-9. PubMed ID: 17173379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects.
    McDonald MG; Tian DD; Thummel KE; Paine MF; Rettie AE
    Drug Metab Dispos; 2020 Oct; 48(10):1018-1027. PubMed ID: 32591416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.
    Relling MV; Nemec J; Schuetz EG; Schuetz JD; Gonzalez FJ; Korzekwa KR
    Mol Pharmacol; 1994 Feb; 45(2):352-8. PubMed ID: 8114683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.